文献速递呼吸危重症与机械通气呼吸道感染

间充质基质细胞修复COVID-19相关ARDS:REALIST-COVID随机对照试验

Repair of Acute Respiratory Distress Syndrome in COVID-19 by Stromal Cells (REALIST-COVID Trial): A Multicenter, Randomized, Controlled Clinical Trial.
PubMed 文献 · Am J Respir Crit Care Med · 2023-01-01

主要安全性终点严重不良事件发生率无显著差异,主要疗效终点第7天氧合指数无差异,次要结局及28天至2年死亡率均无差异。ORBCEL-C安全但未改善肺器官功能障碍的替代指标。

要点

  • ORBCEL-C间充质基质细胞在COVID-19相关ARDS中安全性良好,严重不良事件风险比2.9(95%CI 0.6-13.2;P=0.25)。
  • 第7天氧合指数ORBCEL-C组98.3(57.2)cm H2O/kPa与安慰剂组96.6(67.3)cm H2O/kPa无差异。
  • 次要替代结局、28天至2年死亡率及1年间质性肺疾病患病率均无差异。

核心结论

  • ORBCEL-C间充质基质细胞在中重度COVID-19相关ARDS患者中安全,但未改善肺器官功能障碍的替代指标。

研究设计与样本

  • 多中心、随机、双盲、分配隐藏、安慰剂对照试验(NCT03042143)。
  • 纳入中重度COVID-19相关ARDS患者,随机接受ORBCEL-C(4亿细胞)或安慰剂(Plasma-Lyte 148)。
  • 最终分析ORBCEL-C组30例、安慰剂组29例(安慰剂组1例撤回知情同意)。

主要发现

  • ORBCEL-C组发生6例严重不良事件,安慰剂组3例(风险比2.9,95%CI 0.6-13.2;P=0.25)。
  • 第7天平均(SD)氧合指数ORBCEL-C组98.3(57.2)cm H2O/kPa,安慰剂组96.6(67.3)cm H2O/kPa,无差异。
  • 次要替代结局及第28天、第90天、1年、2年死亡率均无差异。
  • 1年间质性肺疾病患病率及至2年显著医疗事件无差异。
  • ORBCEL-C调节外周血转录组。

临床怎么用

  • ORBCEL-C在此人群中安全性可接受,但现有证据不支持其改善COVID-19相关ARDS肺功能替代指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Mesenchymal stromal cells (MSCs) may modulate inflammation, promoting repair in coronavirus disease (COVID-19)-related acute respiratory distress syndrome (ARDS). Objectives: We investigated the safety and efficacy of ORBCEL-C (CD362 [cluster of differentiation 362]-enriched, umbilical cord-derived MSCs) in COVID-19-related ARDS. Methods: In this multicenter, randomized, double-blind, allocation-concealed, placebo-controlled trial (NCT03042143), patients with moderate to severe COVID-19-related ARDS were randomized to receive ORBCEL-C (400 million cells) or placebo (Plasma-Lyte 148). The primary safety and efficacy outcomes were the incidence of serious adverse events and oxygenation index at Day 7, respectively. Secondary outcomes included respiratory compliance, driving pressure, PaO2:FiO2 ratio, and Sequential Organ Failure Assessment score. Clinical outcomes relating to duration of ventilation, lengths of ICU and hospital stays, and mortality were collected. Long-term follow-up included diagnosis of interstitial lung disease at 1 year and significant medical events and mortality at 2 years. Transcriptomic analysis was performed on whole blood at Days 0, 4, and 7. Measurements and Main Results: Sixty participants were recruited (final analysis: n = 30 received ORBCEL-C, n = 29 received placebo; 1 participant in the placebo group withdrew consent). Six serious adverse events occurred in the ORBCEL-C group and three in the placebo group (risk ratio, 2.9 [95% confidence interval, 0.6-13.2]; P = 0.25). Day 7 mean (SD) oxygenation index did not differ (ORBCEL-C, 98.3 [57.2] cm H2O/kPa; placebo, 96.6 [67.3] cm H2O/kPa). There were no differences in secondary surrogate outcomes or in mortality at Day 28, Day 90, 1 year, or 2 years. There was no difference in the prevalence of interstitial lung disease at 1 year or significant medical events up to 2 years. ORBCEL-C modulated the peripheral blood transcriptome. Conclusion: ORBCEL-C MSCs were safe in subjects with moderate to severe COVID-19-related ARDS but did not improve surrogates of pulmonary organ dysfunction.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Gorman EA, Rynne J, Gardiner HJ, et al. Repair of Acute Respiratory Distress Syndrome in COVID-19 by Stromal Cells (REALIST-COVID Trial): A Multicenter, Randomized, Controlled Clinical Trial. Am J Respir Crit Care Med. 2023. PMID: 37154608. doi:10.1164/rccm.202302-0297OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。